Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Abbott Laboratories: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Abbott Laboratories
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: Abbott Laboratories
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The firm trades with high earnings multiples: 33.31 times its 2026 earnings per share.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Rating Financials

Abbott Laboratories SectorPeru

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Abbott Laboratories SectorPeru

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Abbott Laboratories SectorPeru

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Abbott Laboratories SectorPeru

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Abbott Laboratories SectorPeru

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
202B
BBB
202B
BBB
119B
BBB
61.78B
AA
52.35B
AAA
51.96B
A
34.36B
BBB
30.44B
A
24.87B
AA
24.07B
AA
Average 80.25B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ABT Stock
  4. ABTUS Stock
  5. Ratings Abbott Laboratories